BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li A, Ling Y, Song Z, Cheng X, Ding L, Jiang R, Fu W, Liu Y, Hu H, Yuan S, Chen J, Zhu C, Fan J, Wang J, Jin Y, Zhang M, Zhu L, Sun P, Zhang L, Qin R, Zhang W, Qiu C, Shen Y, Zhang L, Shi Z, Zhao C, Zhu T, Lu H, Zhang X, Xu J. Correlation Between Early Plasma Interleukin 37 Responses With Low Inflammatory Cytokine Levels and Benign Clinical Outcomes in Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis 2021;223:568-80. [PMID: 33197260 DOI: 10.1093/infdis/jiaa713] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Nold-Petry CA, Nold MF. Rationale for IL-37 as a novel therapeutic agent in inflammation. Expert Rev Clin Immunol 2022. [PMID: 35916240 DOI: 10.1080/1744666X.2022.2108792] [Reference Citation Analysis]
2 Makaremi S, Asgarzadeh A, Kianfar H, Mohammadnia A, Asghariazar V, Safarzadeh E. The role of IL-1 family of cytokines and receptors in pathogenesis of COVID-19. Inflamm Res 2022. [PMID: 35751653 DOI: 10.1007/s00011-022-01596-w] [Reference Citation Analysis]
3 Brunt VE, Ikoba AP, Ziemba BP, Ballak DB, Hoischen A, Dinarello CA, Ehringer MA, Seals DR. Circulating interleukin-37 declines with aging in healthy humans: relations to healthspan indicators and IL37 gene SNPs. Geroscience 2022. [PMID: 35622271 DOI: 10.1007/s11357-022-00587-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Fedorchenko Y, Zimba O. CYTOKINES AS POTENTIAL MARKERS OF COVID-19 SEVERITY AND OUTCOMES. CAJMHE 2022;3:10-20. [DOI: 10.47316/cajmhe.2022.3.1.01] [Reference Citation Analysis]
5 Jing X, Xu M, Song D, Yue T, Wang Y, Zhang P, Zhong Y, Zhang M, Lam TT, Faria NR, De Clercq E, Li G. Association between inflammatory cytokines and anti-SARS-CoV-2 antibodies in hospitalized patients with COVID-19. Immun Ageing 2022;19:12. [PMID: 35248063 DOI: 10.1186/s12979-022-00271-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
6 Zhang R, Chen X, Zuo W, Ji Z, Qu Y, Su Y, Yang M, Zuo P, Ma G, Li Y. Inflammatory activation and immune cell infiltration are main biological characteristics of SARS-CoV-2 infected myocardium. Bioengineered 2022;13:2486-97. [PMID: 35037831 DOI: 10.1080/21655979.2021.2014621] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ahmed AA, Ad'hiah AH. Interleukin-37 gene polymorphism and susceptibility to coronavirus disease 19 among Iraqi patients. Meta Gene 2022;31:100989. [PMID: 34729360 DOI: 10.1016/j.mgene.2021.100989] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Ahmed AA, Ad'hiah AH. Interleukin-37 is down-regulated in serum of patients with severe coronavirus disease 2019 (COVID-19). Cytokine 2021;148:155702. [PMID: 34534925 DOI: 10.1016/j.cyto.2021.155702] [Reference Citation Analysis]
9 Law CC, Puranik R, Fan J, Fei J, Hambly BD, Bao S. Clinical Implications of IL-32, IL-34 and IL-37 in Atherosclerosis: Speculative Role in Cardiovascular Manifestations of COVID-19. Front Cardiovasc Med 2021;8:630767. [PMID: 34422917 DOI: 10.3389/fcvm.2021.630767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Su Z, Tao X. Current Understanding of IL-37 in Human Health and Disease. Front Immunol 2021;12:696605. [PMID: 34248996 DOI: 10.3389/fimmu.2021.696605] [Cited by in F6Publishing: 13] [Reference Citation Analysis]